Year: 2023

New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly 19, 2024 PDUFA target action date assigned by the FDAFLORHAM PARK, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the FDA has accepted for review the company’s NDA for VOQUEZNA (vonoprazan) as a daily treatment of heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD) in adults. The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024. “Today...

NORTHVILLE, Mich., Dec. 06, 2023 (GLOBE NEWSWIRE) — Gentherm (NASDAQ: THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Laura Kowalchik has been appointed to the Company’s Board of Directors, effective December 1, 2023. Kowalchik is the Chief Financial Officer of Communications & Power Industries LLC (“CPI”), a global manufacturer of electronic components and subsystems primarily within the communications and defense markets, where she oversees the finance and accounting departments and is actively involved in strategy, M&A and restructuring activities. Prior to joining CPI, Kowalchik served as the Chief Financial Officer of Dayco Incorporated, a global manufacturer...

Top-line data expected in Q2 2024SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company, along with Mundipharma, has completed enrollment in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis. The portion of the trial conducted in China included 52 patients diagnosed with candidemia and/or invasive candidiasis. ReSTORE (NCT03667690) is a global, randomized, double-blind, controlled Phase 3 pivotal clinical trial evaluating the efficacy and safety of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin, the current...

From Premium Chocolate Edibles to Power Packed Drinks, Pre-rolls, and Quality Flower, Find Something Special for the Cannabis Enthusiast on Your List TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, through its wholly-owned licensed subsidiaries, Aphria Inc, and Hexo Operations Inc., and Truss Beverages Company Limited, unveils its 2023 holiday products spotlighting essentials from its diverse portfolio of brands, offering a wide range of options for consumers to explore and share during this festive time of year. For the Chocolate Edibles Connoisseur Chowie Wowie: Premium Chocolate BarsLicensed producer: Aphria Inc.Crunchy Praline: Another 1:1 of 10mg of THC and 10mg of CBD,...

Kalamazoo, Michigan, Dec. 06, 2023 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced today that after 15 years of distinguished service, Dr. Srikant Datar has notified the Company that he will not stand for re-election at Stryker’s 2024 Annual Meeting of Shareholders, which is expected to be held on May 9, 2024. Dr. Datar is the Dean of the Harvard Business School and George F. Baker Professor of Business Administration. He was the Arthur Lowes Dickinson Professor at the Graduate School of Business Administration of Harvard University from 1996 to 2020 and is the former Faculty Chair of the Harvard Innovation Labs and Senior Associate Dean for University Affairs. From 1989 to 1996, Dr. Datar was Edmund W. Littlefield Professor at the Graduate School of Business, Stanford University. Dr. Datar is also a director of ICF International,...

DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract. OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE, help manage knee OA pain. “We are pleased DUROLANE is among the preferred options available...

LOS ANGELES, Dec. 06, 2023 (GLOBE NEWSWIRE) — Clubhouse Media Group, Inc. (OTCMKTS: CMGR) (“CMGR”), a social media firm and digital agency, today announced that HoneyDrip.com is engaging various AI consultants to explore the potential of using AI to support the back-end functions of the site and to enhance processes. The site has also seen month over month growth, continuing into November 2023. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. The site allows creators to connect and engage with fans and monetize exclusive content. HoneyDrip.com has experienced rapid growth in four main categories during the month of November 2023 alone:       1)   Active performers on the site (by Invite Only) increased by 5%       2)   Content posts (photos and videos)...